GE HealthCare (GEHC) 10-Q 30 Apr 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	Apr. 23, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		456,465,369
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 4,650	$ 4,707
Gross profit	1,902	1,891
Selling, general, and administrative	1,038	1,062
Research and development	324	270
Total operating expenses	1,362	1,332
Operating income	540	559
Interest and other financial charges – net	122	136
Non-operating benefit (income) costs	(102)	(115)
Other (income) expense – net	8	(8)
Income before income taxes	512	546
Benefit (provision) for income taxes	(124)	(163)
Net income	388	383
Net (income) loss attributable to noncontrolling interests	(14)	(11)
Net income attributable to GE HealthCare	374	372
Deemed preferred stock dividend of redeemable noncontrolling interest	0	(183)
Net income attributable to GE HealthCare common stockholders	$ 374	$ 189
Earnings per share attributable to GE HealthCare common stockholders:
Basic earnings per share (in dollars per share)	$ 0.82	$ 0.42
Diluted earnings per share (in dollars per share)	$ 0.81	$ 0.41
Weighted-average number of shares outstanding:
Basic (in shares)	456	454
Diluted (in shares)	459	457
Cost of products
Total revenues	$ 3,045	$ 3,131
Cost of revenue	1,967	2,037
Cost of services
Total revenues	1,605	1,576
Cost of revenue	$ 782	$ 779

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 374	$ 372
Net (income) loss attributable to noncontrolling interests	14	11
Net income	388	383
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	(76)	57
Pension and Other Postretirement Plans – net of taxes	(35)	(65)
Cash flow hedges – net of taxes	16	(39)
Other comprehensive income (loss)	(95)	(47)
Comprehensive income (loss)	292	336
Less: Comprehensive income (loss) attributable to noncontrolling interests	14	11
Comprehensive income attributable to GE HealthCare	$ 278	$ 325

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Cash, cash equivalents, and restricted cash	$ 2,563	$ 2,504
Inventories	1,989	1,960
Contract and other deferred assets	961	1,000
All other current assets	517	389
Current assets	9,373	9,410
Property, plant, and equipment – net	2,445	2,500
Goodwill	12,927	12,936
Other intangible assets – net	1,174	1,253
Deferred income taxes	4,413	4,474
All other non-current assets	1,878	1,881
Total assets	32,208	32,454
Short-term borrowings	1,008	1,006
Accounts payable	2,931	2,947
Contract liabilities	1,879	1,918
Current liabilities	8,859	8,981
Long-term borrowings	8,247	8,436
Compensation and benefits	5,625	5,782
Deferred income taxes	68	68
All other non-current liabilities	1,811	1,877
Total liabilities	24,609	25,144
Commitments and contingencies
Redeemable noncontrolling interests	177	165
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 456,328,270 shares issued and outstanding as of March 31, 2024; 455,342,290 shares issued and outstanding as of December 31, 2023	5	5
Additional paid-in capital	6,504	6,493
Retained earnings	1,687	1,326
Accumulated other comprehensive income (loss) – net	(787)	(691)
Total equity attributable to GE HealthCare	7,408	7,133
Noncontrolling interests	14	12
Total equity	7,423	7,145
Total liabilities, redeemable noncontrolling interests, and equity	32,208	32,454
Nonrelated party
Receivables, net	3,324	3,525
All other current liabilities	2,993	3,011
Related party
Receivables, net	20	32
All other non-current assets	80	81
All other current liabilities	48	99
All other non-current liabilities	$ 33	$ 33

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 102	$ 98
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	456,328,270	455,342,290
Common stock, outstanding (in shares)	456,328,270	455,342,290

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2022		0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0	$ 0	$ 0	$ 11,235	$ (1,878)	$ 5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from GE, including Spin-Off-related adjustments	(2,834)				(4,833)	2,000	(1)
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5	6,397		(6,402)
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes (in shares)		1,000,000
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes	4		4
Net income attributable to GE HealthCare	372			372
Other comprehensive income (loss) attributable to GE HealthCare	(47)					(47)
Changes in equity attributable to noncontrolling interests	2						2
Share-based compensation	24		24
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	(187)			(187)
Equity, ending balance (in shares) at Mar. 31, 2023		455,000,000
Equity, ending balance at Mar. 31, 2023	$ 6,696	$ 5	6,425	185	$ 0	75	6
Equity, beginning balance (in shares) at Dec. 31, 2023	455,342,290	455,000,000
Equity, beginning balance at Dec. 31, 2023	$ 7,145	$ 5	6,493	1,326		(691)	12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes (in shares)		1,000,000
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes	(24)		(24)
Net income attributable to GE HealthCare	374			374
Dividends declared	(14)			(14)
Other comprehensive income (loss) attributable to GE HealthCare	(95)					(95)
Changes in equity attributable to noncontrolling interests	2						2
Share-based compensation	$ 34		34
Equity, ending balance (in shares) at Mar. 31, 2024	456,328,270	456,000,000
Equity, ending balance at Mar. 31, 2024	$ 7,423	$ 5	$ 6,504	$ 1,687		$ (787)	$ 14

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2024 $ / shares
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.03

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows - operating activities
Net income	$ 388	$ 383
Adjustments to reconcile Net income to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	68	61
Amortization of intangible assets	80	96
Gain on fair value remeasurement of contingent consideration	(1)	0
Net periodic postretirement benefit plan (income) expense	(90)	(101)
Postretirement plan contributions	(87)	(91)
Share-based compensation	34	24
Provision for income taxes	124	163
Cash paid during the year for income taxes	(86)	(102)
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	155	(22)
Due from related parties	13	5
Inventories	(59)	(122)
Contract and other deferred assets	32	12
Accounts payable	81	87
Due to related parties	(50)	6
Contract liabilities	(18)	119
All other operating activities	(165)	(50)
Cash from (used for) operating activities	419	468
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(145)	(143)
Purchases of businesses, net of cash acquired	0	(127)
All other investing activities	(42)	4
Cash from (used for) investing activities	(188)	(266)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	1	(9)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	1	2,000
Repayments and other reductions (maturities longer than 90 days)	(153)	(6)
Dividends paid to stockholders	(14)	0
Net transfers (to) from GE	0	(1,317)
All other financing activities	12	5
Cash from (used for) financing activities	(153)	673
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(19)	8
Increase (decrease) in cash, cash equivalents, and restricted cash	59	883
Cash, cash equivalents, and restricted cash at beginning of year	2,506	1,451
Cash, cash equivalents, and restricted cash as of March 31	2,565	2,334
Supplemental disclosure of cash flows information
Cash paid during the year for interest	(55)	(42)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$ 53	$ 64

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023 (the “Distribution Date”), the General Electric Company (“GE”) completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE’s common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. As of March 31, 2024, GE’s beneficial ownership was approximately 6.7% of the Company’s outstanding common stock. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,834 million. These items substantially consisted of the transfer of: (1) certain pension plan liabilities and assets, (2) certain deferred income taxes, (3) deferred compensation liabilities, and (4) employee termination obligations. In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 17, “Related Parties” for more information on these agreements and related transactions. The condensed consolidated financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated financial statements. Operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The following tables are presented in millions of U.S. dollars unless otherwise stated. Certain columns and rows throughout this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. The condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated and combined financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. RECENT ACCOUNTING PRONOUNCEMENTS. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

REVENUE RECOGNITION

REVENUE RECOGNITION	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as on-demand service parts and maintenance services, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. CONTRACT ASSETS. Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs. Contract and Other Deferred Assets As of March 31, 2024 December 31, 2023 Contract assets $ 577 $ 600 Other deferred assets 384 400 Contract and other deferred assets 961 1,000 Non-current contract assets (1) 78 72 Non-current other deferred assets (1) 97 96 Total contract and other deferred assets $ 1,136 $ 1,168 (1) Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. CONTRACT LIABILITIES. Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations (“RPO”) are expected to be satisfied with our customers. As of March 31, 2024 and December 31, 2023, contract liabilities were approximately $2,566 million and $2,623 million, respectively, of which the non-current portion of $687 million and $705 million, respectively, was recognized in All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. Contract liabilities decreased $56 million in 2024 primarily due to a decrease in customer advances. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $741 million and $759 million for the three months ended March 31, 2024 and 2023, respectively. REMAINING PERFORMANCE OBLIGATIONS. RPO represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of March 31, 2024, the aggregate amount of the contracted revenues allocated to our unsatisfied performance obligations was $14,313 million. We expect to recognize revenue as we satisfy our RPO as follows: a) product-related RPO of $4,742 million of which 98% is expected to be recognized within two years, and the remaining thereafter; and b) services-related RPO of $9,570 million of which 65% and 94% are expected to be recognized within two years and five years, respectively, and the remaining thereafter.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss). Total Revenues by Segment For the three months ended March 31 2024 2023 Imaging: Radiology $ 2,062 $ 2,088 Interventional Guidance 403 408 Total Imaging 2,466 2,496 Total Ultrasound 824 859 PCS: Monitoring Solutions 527 552 Life Support Solutions 220 229 Total PCS 747 781 Total PDx 599 558 Other (1) 15 13 Total revenues $ 4,650 $ 4,707 (1) Financial information not presented within the reportable segments, shown within the Other category, represents the Hea lthCar e Financial Services (“HFS”) business which does not meet the definition of an operating segment. Segment EBIT For the three months ended March 31 2024 2023 Segment EBIT Imaging $ 240 $ 191 Ultrasound 182 207 PCS 81 109 PDx 178 155 Other (1) (1) 2 681 664 Restructuring costs (40) (12) Acquisition and disposition-related benefits (charges) — (1) Gain (loss) on business and asset dispositions — — Spin-Off and separation costs (60) (58) Amortization of acquisition-related intangible assets (31) (31) Investment revaluation gain (loss) (20) 5 Interest and other financial charges – net (122) (136) Non-operating benefit income (costs) 102 115 Income before income taxes $ 512 $ 546 (1) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

RECEIVABLES

RECEIVABLES	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Current Receivables As of March 31, 2024 December 31, 2023 Current customer receivables (1) $ 3,148 $ 3,339 Non-income based tax receivables 151 166 Other sundry receivables 127 118 Current sundry receivables 278 284 Allowance for credit losses (102) (98) Total current receivables – net $ 3,324 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $136 million and $144 million as of March 31, 2024 and December 31, 2023, respectively. Long-Term Receivables As of March 31, 2024 December 31, 2023 Long-term customer receivables $ 57 $ 55 Non-income based tax receivables 25 26 Other sundry receivables 78 73 Long-term sundry receivables 102 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 130 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

FINANCING RECEIVABLES

FINANCING RECEIVABLES	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
FINANCING RECEIVABLES	FINANCING RECEIVABLES Financing Receivables As of March 31, 2024 December 31, 2023 Loans, net of deferred income $ 29 $ 29 Investment in financing leases, net of deferred income 71 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 96 97 Loans, net of deferred income 36 37 Investment in financing leases, net of deferred income 149 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 181 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position. As of March 31, 2024 , 6%, 5%, and 7% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2023 , 5%, 5%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	LEASES Operating lease liabilities recognized within All other current liabilities and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position were $376 million and $383 million as of March 31, 2024 and December 31, 2023, respectively. The total lease expense related to our operating lease portfolio was $60 million and $56 million for the three months ended March 31, 2024 and 2023, respectively.

ACQUISITIONS, GOODWILL, AND OTH

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users. GOODWILL. Balance as of December 31, 2023 Acquisitions Foreign exchange and other Balance as of March 31, 2024 Imaging $ 4,431 $ — $ (4) $ 4,427 Ultrasound 3,933 — (5) 3,928 PCS 2,038 — (1) 2,037 PDx 2,534 — — 2,534 Total Goodwill $ 12,936 $ — $ (10) $ 12,927 We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date. OTHER INTANGIBLE ASSETS. Intangible assets decreased during the three months ended March 31, 2024, primarily as a result of amortization. Substantially all of our intangible assets are subject to amortization. Amortization expense was $80 million and $96 million for the three months ended March 31, 2024 and 2023, respectively.
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users. GOODWILL. Balance as of December 31, 2023 Acquisitions Foreign exchange and other Balance as of March 31, 2024 Imaging $ 4,431 $ — $ (4) $ 4,427 Ultrasound 3,933 — (5) 3,928 PCS 2,038 — (1) 2,037 PDx 2,534 — — 2,534 Total Goodwill $ 12,936 $ — $ (10) $ 12,927 We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date. OTHER INTANGIBLE ASSETS. Intangible assets decreased during the three months ended March 31, 2024, primarily as a result of amortization. Substantially all of our intangible assets are subject to amortization. Amortization expense was $80 million and $96 million for the three months ended March 31, 2024 and 2023, respectively.

BORROWINGS

BORROWINGS	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
BORROWINGS	BORROWINGS The Company’s borrowings include the following senior unsecured notes and credit agreements: Senior Unsecured Notes The Company’s borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). Refer to the table below for further information about the Notes. Credit Facilities The Company has credit agreements providing for: • a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million; • a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million; and • a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”). There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility as of March 31, 2024 or December 31, 2023. In the first quarter of 2024, we repaid $150 million of the outstanding Term Loan Facility. As of March 31, 2024, we have repaid a total of $1,000 million of this facility. We had no principal debt repayments on the Notes for the three months ended March 31, 2024. Borrowings Composition As of March 31, 2024 December 31, 2023 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility due January 2, 2026 1,000 1,150 Other 51 52 Total principal debt issued 9,301 9,452 Less: Unamortized debt issuance costs and discounts 33 35 Add: Cumulative basis adjustment for fair value hedges (13) 25 Total borrowings 9,255 9,442 Less: Short-term borrowings (1) 1,008 1,006 Long-term borrowings $ 8,247 $ 8,436 (1) Short-term borrowings as of March 31, 2024 and December 31, 2023 i ncludes $1,003 million and $1,002 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts. See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts. LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS. As of March 31, 2024 and December 31, 2023, the Company had bank guarantees and surety bonds of approximately $717 million and $751 million, respectively, related to certain commercial contracts. Additionally, we have approximately $33 million and $39 million of guarantees as of March 31, 2024 and December 31, 2023, respectively, primarily related to residual and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated Statements of Financial Position reflect a liability of $4 million as of March 31, 2024 and December 31, 2023 related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

POSTRETIREMENT BENEFIT PLANS

POSTRETIREMENT BENEFIT PLANS	3 Months Ended
	Mar. 31, 2024
Retirement Benefits [Abstract]
POSTRETIREMENT BENEFIT PLANS	POSTRETIREMENT BENEFIT PLANS We sponsor a number of pension and retiree health and life insurance benefit plans that we present in three categories, Principal Pension Plans, Other Pension Plans, and Other Postretirement Plans (“OPEB Plans”). Please refer to Note 10, “Postretirement Benefit Plans” to the consolidated and combined financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for further information. On January 1, 2024, we transitioned from legacy GE multiple-employer OPEB plans to GE HealthCare sponsored single-employer OPEB plans. This change did not have an impact on our results of operations or financial position. Pension plans with pension assets or obligations less than $50 million are not included in the results below. Components of Expense (Income) For the three months ended March 31 Principal Pension Plans Other Pension Plans OPEB Plans 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 7 $ 8 $ 6 $ 6 $ 2 $ 2 Interest cost 227 240 50 52 13 15 Expected return on plan assets (283) (293) (63) (63) — — Amortization of net loss (gain) (19) (31) 5 2 (15) (16) Amortization of prior service cost (credit) 2 — — (1) (22) (22) Non-operating $ (73) $ (84) $ (8) $ (10) $ (24) $ (23) Net periodic expense (income) $ (66) $ (76) $ (2) $ (4) $ (22) $ (21) In the three months ended March 31, 2024, the Company made cash benefit payments totaling $27 million to its Principal Pension Plans, $21 million to its Other Pension Plans, and $39 million to its OPEB Plans. In 2024, the Company expects to make total cash contributions of approximately $336 million to these plans. The Company does not have a required minimum funding contribution for its U.S.-based GE HealthCare Pension Plan in 2024. Future contributions will depend on market conditions, interest rates, and other factors. Defined Contribution Plan GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees . Expenses associated with

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our effective income tax rate was 24.2% and 29.9% for the three months ended March 31, 2024 and 2023, respectively. The tax rate for the three months ended March 31, 2024 and 2023 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations, withholding taxes, and state taxes. Post Spin-Off, the Company’s previously undistributed earnings of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in the first quarter of 2023, an incremental deferred tax liability of $30 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. The Company is currently being audited in a number of jurisdictions for tax years 2004-2022, including China, Germany, Norway, the United Kingdom, and the United States.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET Changes in Accumulated other comprehensive income (loss) ( “ AOCI”) by component, net of income taxes, were as follows. For the three months ended March 31, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2023 $ (1,706) $ 1,033 $ (18) $ (691) Other comprehensive income (loss) before reclassifications – net of taxes of $(7), $(1), and $(4) (76) 2 15 (58) Reclassifications from AOCI – net of taxes (2) of $0, $12, and $0 — (38) — (37) Other comprehensive income (loss) (76) (35) 16 (95) Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — March 31, 2024 $ (1,781) $ 997 $ (2) $ (787) For the three months ended March 31, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclassifications – net of taxes of $(11), $2, and $4 57 (13) (13) 31 Reclassifications from AOCI – net of taxes (2) of $0, $16, and $7 — (52) (26) (78) Other comprehensive income (loss) 57 (65) (39) (47) Spin-Off related adjustments – net of taxes of $0, $(509), and $0 28 1,972 — 2,000 Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — March 31, 2023 $ (1,760) $ 1,865 $ (30) $ 75 (1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three months ended March 31, 2024 and 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements.” (2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS DERIVATIVES AND HEDGING. Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, equity prices, and commodity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes. Cash Flow Hedges For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of March 31, 2024, we expect to reclassify $3 million of pre-tax net deferred losses associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions. Net Investment Hedges We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of March 31, 2024, these contracts were designated as hedges of our net investment in foreign operations with Euro, Japanese Yen, and Chinese Renminbi functional currencies. Fair Value Hedges We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges. In the first quarter of 2024, we executed interest rate swap contracts to hedge the benchmark interest rate risk of specific designated cash flows of our senior unsecured notes. We record the changes in fair value on the swap contracts in Interest and other financial charges – net in our Condensed Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment. Derivatives Not Designated as Hedging Instrument s We also execute derivative instruments, such as foreign currency forward contracts, equity-linked total return swaps, and commodity forward contracts that are not designated as qualifying hedges. These derivatives serve as economic hedges of the foreign currency rate risk, equity price risk and commodity price risk. We identify foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of a substantive party to the contract and record them as embedded derivatives. The changes in fair value of derivatives not designated in qualifying hedge transactions are recorded in Cost of products, Cost of services, Selling, general, and administrative (“SG&A”), and Other (income) expense – net in the Condensed Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Condensed Consolidated Statements of Income. The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives March 31, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,176 $ 15 $ 15 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,176 15 15 1,356 8 30 Cross-currency swaps (1) 2,178 — 174 2,209 — 204 Foreign currency forward and options contracts 976 10 8 991 9 11 Derivatives accounted for as net investment hedges 3,154 10 182 3,200 9 215 Interest rate swaps (1) 1,700 3 16 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 3 16 1,000 35 10 Foreign currency forward contracts 3,586 8 15 3,597 19 12 Other derivatives (2) 375 78 1 438 57 2 Derivatives not designated as hedging instruments 3,961 87 17 4,035 76 14 Total derivatives $ 9,991 $ 115 $ 230 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts. The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges. March 31, 2024 December 31, 2023 Carrying amount Cumulative basis adjustment included in the carrying amount Carrying amount Cumulative basis adjustment included in the carrying amount Long-term borrowings designated in fair value hedges $ 1,683 $ (13) $ 1,023 $ 25 Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Condensed Consolidated Statements of Financial Position and in the table above. As of March 31, 2024, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $40 million. The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges. Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended March 31 2024 2023 Cash flow hedges $ 20 $ (17) Net investment hedges (1) 32 35 (1) Amounts recognized in OCI for excluded components for the periods presented were immaterial. The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income. Derivative Financial Instruments and Hedging Activity For the three months ended March 31, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (3) Foreign currency forward contracts $ (1) $ — $ — $ — $ — Effects of cash flow hedges (1) — — — — Cross-currency swaps — — — 8 — Foreign currency forward and options contracts — — — 2 — Effects of net investment hedges (1) — — — 10 — Interest rate swaps (4) — — — (45) — Debt basis adjustment on Long-term borrowings — — — 38 — Effects of fair value hedges — — — (6) — Foreign currency forward contracts (12) (3) — — — Other derivatives (2) — — 5 — 20 Effects of derivatives not designated as hedging instruments $ (12) $ (3) $ 5 $ — $ 20 For the three months ended March 31, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (3) Foreign currency forward contracts $ 27 $ 6 $ — $ — $ — Effects of cash flow hedges 27 6 — — — Cross-currency swaps — — — 9 — Foreign currency forward and option contracts — — — — — Effects of net investment hedges (1) — — — 9 — Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts 7 2 — — 1 Other derivatives (2) — — 15 — — Effects of derivatives not designated as hedging instruments $ 7 $ 2 $ 15 $ — $ 1 (1) Amounts are excluded from effectiveness testing for the three months ended March 31, 2024 and 2023. (2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives. (3) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income. (4) Amount includes $(6) million of interest expense on interest rate derivatives. FAIR VALUE MEASUREMENTS. The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis. Fair Value of Assets and Liabilities Measured on a Recurring Basis As of March 31, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Investment securities $ 28 $ — $ — $ 28 $ 31 $ — $ — $ 31 Derivatives — 115 — 115 — 128 — 128 Liabilities: Deferred compensation 263 5 — 268 264 5 — 269 Derivatives — 230 — 230 — 269 — 269 Contingent consideration — — 41 41 — — 44 44 Deferred compensation The deferred compensation liabilities as of March 31, 2024 and December 31, 2023 are comprised of market-based obligations indexed to the S&P 500 index fund and GE HealthCare stock in Level 1, and mutual funds in Level 2. Contingent Consideration The contingent consideration liabilities as of March 31, 2024 and December 31, 2023 were recorded in connection with business acquisitions. Non-recurring Fair Value Measurements Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the three months ended March 31, 2024 and 2023. Fair Value of Other Financial Instruments The estimated fair value of borrowings as of March 31, 2024 and December 31, 2023 was $9,807 million and $9,959 million, respectively, compared to a carrying value (which includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $9,255 million and $9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” for further information.

COMMITMENTS, GUARANTEES, PRODUC

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES GUARANTEES. The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information. Following the Spin-Off, which was completed pursuant to a Separation and Distribution Agreement (the “Separation and Distribution Agreement”), the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of March 31, 2024 the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $114 million. PRODUCT WARRANTIES. We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows. For the three months ended March 31 2024 2023 Balance at beginning of period $ 192 $ 193 Current-year provisions 41 49 Expenditures (55) (51) Other changes (2) 2 Balance at end of period $ 175 $ 193 Product warranties are recognized within All other current liabilities in the Condensed Consolidated Statements of Financial Position. LEGAL MATTERS. In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated. Contracts with Iraqi Ministry of Health In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On October 2, 2023, the Supreme Court invited the Solicitor General to file a brief in this case expressing the views of the United States. The proceedings in the District Court are currently inactive. Government Disclosures From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntary self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

RESTRUCTURING AND OTHER ACTIVIT

RESTRUCTURING AND OTHER ACTIVITIES - NET	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND OTHER ACTIVITIES - NET	RESTRUCTURING AND OTHER ACTIVITIES – NET Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring and other activities are not allocated. For restructuring initiatives committed to by management through March 31, 2024, including additional initiatives committed to in the three months ended March 31, 2024, we recorded net expenses of $40 million and $12 million for the three months ended March 31, 2024 and 2023, respectively. These restructuring initiatives are expected to result in additional expenses of approximately $25 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Condensed Consolidated Statements of Income. Restructuring and Other Activities For the three months ended March 31 2024 2023 Employee termination costs $ 25 $ 10 Facility and other exit costs 8 1 Asset write-downs 7 1 Total restructuring and other activities – net $ 40 $ 12

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The numerator for both basic and diluted earnings per share (“EPS”) is net income attributable to GE HealthCare common stockholders. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units, and performance share units is reflected in the denominator for diluted EPS using the treasury stock method. Earnings Per Share For the three months ended March 31 (In millions, except per share amounts) 2024 2023 Numerator: Net income $ 388 $ 383 Net (income) loss attributable to noncontrolling interests (14) (11) Net income attributable to GE HealthCare 374 372 Deemed preferred stock dividend of redeemable noncontrolling interest — (183) Net income attributable to GE HealthCare common stockholders $ 374 $ 189 Denominator: Basic weighted-average shares outstanding 456 454 Dilutive effect of common stock equivalents 3 3 Diluted weighted-average shares outstanding 459 457 Basic earnings per share $ 0.82 $ 0.42 Diluted earnings per share $ 0.81 $ 0.41 Antidilutive securities (1) 4 4 (1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	SUPPLEMENTAL FINANCIAL INFORMATION Cash, Cash Equivalents, and Restricted Cash As of March 31, 2024 December 31, 2023 Cash and cash equivalents $ 2,551 $ 2,494 Short-term restricted cash 12 10 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Financial Position 2,563 2,504 Long-term restricted cash (1) 2 2 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Cash Flows $ 2,565 $ 2,506 (1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Inventories As of March 31, 2024 December 31, 2023 Raw materials $ 927 $ 961 Work in process 101 91 Finished goods 961 908 Inventories (1) $ 1,989 $ 1,960 (1) Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Property, Plant, and Equipment – Net As of March 31, 2024 December 31, 2023 Original cost $ 5,180 $ 5,208 Accumulated depreciation (3,089) (3,064) Right-of-use operating lease assets, net of amortization 354 356 Property, plant, and equipment – net $ 2,445 $ 2,500 All Other Current and Non-Current Assets As of March 31, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 244 $ 147 Financing receivables – net 96 97 Derivative instruments 101 84 Other (1) 75 61 All other current assets $ 517 $ 389 Prepaid pension asset 727 716 Equity method and other investments 346 357 Financing receivables – net 181 178 Long-term receivables – net 130 124 Inventories 154 147 Contract and other deferred assets 175 168 Other (2) 165 191 All other non-current assets $ 1,878 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of indemnities due from GE, capitalized cloud computing software, tax receivables and derivative instruments. All Other Current and Non-Current Liabilities As of March 31, 2024 December 31, 2023 Employee compensation and benefit liabilities (1) $ 1,502 $ 1,518 Sales allowances and related liabilities 208 228 Income and indirect tax liabilities including uncertain tax positions 266 260 Product warranties 175 192 Accrued freight and utilities 113 132 Operating lease liabilities 109 110 Derivative instruments (2) 110 128 Interest payable on borrowings 170 87 Environmental and asset retirement obligations 20 21 Other (3) 318 335 All other current liabilities $ 2,993 $ 3,011 Contract liabilities 687 705 Operating lease liabilities 267 273 Environmental and asset retirement obligations 265 265 Income and indirect tax liabilities including uncertain tax positions 207 208 Derivative instruments 114 136 Finance lease obligations 37 38 Sales allowances and related liabilities 24 27 Other (4) 209 225 All other non-current liabilities $ 1,811 $ 1,877 (1) Employee compensation and benefit liabilities consists of incentive compensation and commissions, pension and other postretirement benefit obligations, payroll accruals, other employee related liabilities, and deferred compensation. (2) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to stockholders, and contingent consideration liabilities. (4) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE. SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements. Included within Accounts payable in the Condensed Consolidated Statements of Financial Position as of March 31, 2024 and December 31, 2023 were $384 million and $365 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs. REDEEMABLE NONCONTROLLING INTERESTS . The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value. The activity attributable to redeemable noncontrolling interests for the three months ended March 31, 2024 and 2023 is presented below. Redeemable Noncontrolling Interests For the three months ended March 31 2024 2023 Balance at beginning of period $ 165 $ 230 Net income attributable to redeemable noncontrolling interests 11 10 Redemption value adjustments (1) — 183 Distributions to and exercise of redeemable noncontrolling interests and other (2) — (222) Balance at end of period $ 177 $ 201 (1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings. (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The expected redemption payment of $211 million was recognized within All other current liabilities as of March 31, 2023 and was subsequently paid out in the second quarter of 2023. Other Income (Expense) – Net For the three months ended March 31 2024 2023 Net financing income and investment income (loss) $ (16) $ 13 Equity method income (loss) 1 4 Change in fair value of assumed obligations (8) (13) Other items, net (1) 14 4 Total other income (expense) – net $ (8) $ 8 (1) Other items, net primarily consists of change in tax indemnities with GE, lease income, gains and losses related to derivatives, and licensing and royalty income for the three months ended March 31, 2024, and lease income, gains and losses related to derivatives, and licensing and royalty income for the three months ended March 31, 2023.

RELATED PARTIES

RELATED PARTIES	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including the Transition Services Agreement (“TSA”). For the three months ended March 31, 2024 and 2023, we incurred $53 million, net, and $108 million, net, respectively, under the TSA which represents fees charged from GE to the Company primarily for information technology, human resources, and research and development and is net of fees charged from the Company to GE for facilities and other shared services. Current amounts due from and to GE under the various agreements are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated Statements of Financial Position. Non-current amounts due from GE were $80 million and $81 million, and due to GE were $33 million and $33 million, as of March 31, 2024 and December 31, 2023, respectively. These amounts were recognized within All other non-current assets and All other non-current liabilities, respectively, in the Condensed Consolidated Statements of Financial Position and primarily relate to tax and other indemnities. For more information on these arrangements, see Note 19, “Related Parties” to the consolidated and combined financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $258 million, net of cash acquired, and up to $35 million in cash upon the completion of certain milestones and service requirements. The acquisition was funded with cash on hand. The Company is in the process of measuring the acquired assets and assumed liabilities as of the acquisition date. MIM Software is a global provider of medical imaging analysis and AI solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. The addition of MIM Software to GE HealthCare’s portfolio is expected to strengthen the Company’s response to provider needs, supplying established solutions that are designed to help simplify, streamline, and automate essential tasks to enhance workflow.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 374	$ 372

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	The condensed consolidated financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated financial statements. Operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The following tables are presented in millions of U.S. dollars unless otherwise stated. Certain columns and rows throughout this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Summary of Contract and Other Deferred Assets	Contract and Other Deferred Assets As of March 31, 2024 December 31, 2023 Contract assets $ 577 $ 600 Other deferred assets 384 400 Contract and other deferred assets 961 1,000 Non-current contract assets (1) 78 72 Non-current other deferred assets (1) 97 96 Total contract and other deferred assets $ 1,136 $ 1,168 (1) Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Total Revenues by Segment For the three months ended March 31 2024 2023 Imaging: Radiology $ 2,062 $ 2,088 Interventional Guidance 403 408 Total Imaging 2,466 2,496 Total Ultrasound 824 859 PCS: Monitoring Solutions 527 552 Life Support Solutions 220 229 Total PCS 747 781 Total PDx 599 558 Other (1) 15 13 Total revenues $ 4,650 $ 4,707 (1) Financial information not presented within the reportable segments, shown within the Other category, represents the Hea lthCar e Financial Services (“HFS”) business which does not meet the definition of an operating segment. Segment EBIT For the three months ended March 31 2024 2023 Segment EBIT Imaging $ 240 $ 191 Ultrasound 182 207 PCS 81 109 PDx 178 155 Other (1) (1) 2 681 664 Restructuring costs (40) (12) Acquisition and disposition-related benefits (charges) — (1) Gain (loss) on business and asset dispositions — — Spin-Off and separation costs (60) (58) Amortization of acquisition-related intangible assets (31) (31) Investment revaluation gain (loss) (20) 5 Interest and other financial charges – net (122) (136) Non-operating benefit income (costs) 102 115 Income before income taxes $ 512 $ 546 (1) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of March 31, 2024 December 31, 2023 Current customer receivables (1) $ 3,148 $ 3,339 Non-income based tax receivables 151 166 Other sundry receivables 127 118 Current sundry receivables 278 284 Allowance for credit losses (102) (98) Total current receivables – net $ 3,324 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $136 million and $144 million as of March 31, 2024 and December 31, 2023, respectively. Long-Term Receivables As of March 31, 2024 December 31, 2023 Long-term customer receivables $ 57 $ 55 Non-income based tax receivables 25 26 Other sundry receivables 78 73 Long-term sundry receivables 102 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 130 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Financing Receivables As of March 31, 2024 December 31, 2023 Loans, net of deferred income $ 29 $ 29 Investment in financing leases, net of deferred income 71 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 96 97 Loans, net of deferred income 36 37 Investment in financing leases, net of deferred income 149 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 181 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.

FINANCING RECEIVABLES (Tables)

FINANCING RECEIVABLES (Tables)	3 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of March 31, 2024 December 31, 2023 Current customer receivables (1) $ 3,148 $ 3,339 Non-income based tax receivables 151 166 Other sundry receivables 127 118 Current sundry receivables 278 284 Allowance for credit losses (102) (98) Total current receivables – net $ 3,324 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $136 million and $144 million as of March 31, 2024 and December 31, 2023, respectively. Long-Term Receivables As of March 31, 2024 December 31, 2023 Long-term customer receivables $ 57 $ 55 Non-income based tax receivables 25 26 Other sundry receivables 78 73 Long-term sundry receivables 102 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 130 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Financing Receivables As of March 31, 2024 December 31, 2023 Loans, net of deferred income $ 29 $ 29 Investment in financing leases, net of deferred income 71 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 96 97 Loans, net of deferred income 36 37 Investment in financing leases, net of deferred income 149 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 181 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.

ACQUISITIONS, GOODWILL, AND O_2

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	GOODWILL. Balance as of December 31, 2023 Acquisitions Foreign exchange and other Balance as of March 31, 2024 Imaging $ 4,431 $ — $ (4) $ 4,427 Ultrasound 3,933 — (5) 3,928 PCS 2,038 — (1) 2,037 PDx 2,534 — — 2,534 Total Goodwill $ 12,936 $ — $ (10) $ 12,927

BORROWINGS (Tables)

BORROWINGS (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Borrowings	Borrowings Composition As of March 31, 2024 December 31, 2023 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility due January 2, 2026 1,000 1,150 Other 51 52 Total principal debt issued 9,301 9,452 Less: Unamortized debt issuance costs and discounts 33 35 Add: Cumulative basis adjustment for fair value hedges (13) 25 Total borrowings 9,255 9,442 Less: Short-term borrowings (1) 1,008 1,006 Long-term borrowings $ 8,247 $ 8,436 (1) Short-term borrowings as of March 31, 2024 and December 31, 2023 i ncludes $1,003 million and $1,002 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

POSTRETIREMENT BENEFIT PLANS (T

POSTRETIREMENT BENEFIT PLANS (Tables)	3 Months Ended
	Mar. 31, 2024
Retirement Benefits [Abstract]
Components of Net Periodic Expense	Components of Expense (Income) For the three months ended March 31 Principal Pension Plans Other Pension Plans OPEB Plans 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 7 $ 8 $ 6 $ 6 $ 2 $ 2 Interest cost 227 240 50 52 13 15 Expected return on plan assets (283) (293) (63) (63) — — Amortization of net loss (gain) (19) (31) 5 2 (15) (16) Amortization of prior service cost (credit) 2 — — (1) (22) (22) Non-operating $ (73) $ (84) $ (8) $ (10) $ (24) $ (23) Net periodic expense (income) $ (66) $ (76) $ (2) $ (4) $ (22) $ (21)

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in Accumulated other comprehensive income (loss) ( “ AOCI”) by component, net of income taxes, were as follows. For the three months ended March 31, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2023 $ (1,706) $ 1,033 $ (18) $ (691) Other comprehensive income (loss) before reclassifications – net of taxes of $(7), $(1), and $(4) (76) 2 15 (58) Reclassifications from AOCI – net of taxes (2) of $0, $12, and $0 — (38) — (37) Other comprehensive income (loss) (76) (35) 16 (95) Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — March 31, 2024 $ (1,781) $ 997 $ (2) $ (787) For the three months ended March 31, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclassifications – net of taxes of $(11), $2, and $4 57 (13) (13) 31 Reclassifications from AOCI – net of taxes (2) of $0, $16, and $7 — (52) (26) (78) Other comprehensive income (loss) 57 (65) (39) (47) Spin-Off related adjustments – net of taxes of $0, $(509), and $0 28 1,972 — 2,000 Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — March 31, 2023 $ (1,760) $ 1,865 $ (30) $ 75 (1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three months ended March 31, 2024 and 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements.” (2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Derivative Assets at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives March 31, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,176 $ 15 $ 15 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,176 15 15 1,356 8 30 Cross-currency swaps (1) 2,178 — 174 2,209 — 204 Foreign currency forward and options contracts 976 10 8 991 9 11 Derivatives accounted for as net investment hedges 3,154 10 182 3,200 9 215 Interest rate swaps (1) 1,700 3 16 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 3 16 1,000 35 10 Foreign currency forward contracts 3,586 8 15 3,597 19 12 Other derivatives (2) 375 78 1 438 57 2 Derivatives not designated as hedging instruments 3,961 87 17 4,035 76 14 Total derivatives $ 9,991 $ 115 $ 230 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.
Schedule of Derivative Liabilities at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives March 31, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,176 $ 15 $ 15 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,176 15 15 1,356 8 30 Cross-currency swaps (1) 2,178 — 174 2,209 — 204 Foreign currency forward and options contracts 976 10 8 991 9 11 Derivatives accounted for as net investment hedges 3,154 10 182 3,200 9 215 Interest rate swaps (1) 1,700 3 16 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 3 16 1,000 35 10 Foreign currency forward contracts 3,586 8 15 3,597 19 12 Other derivatives (2) 375 78 1 438 57 2 Derivatives not designated as hedging instruments 3,961 87 17 4,035 76 14 Total derivatives $ 9,991 $ 115 $ 230 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.
Effect of Derivatives Instruments on Statement of Financial Position and Statement of Income	The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges. March 31, 2024 December 31, 2023 Carrying amount Cumulative basis adjustment included in the carrying amount Carrying amount Cumulative basis adjustment included in the carrying amount Long-term borrowings designated in fair value hedges $ 1,683 $ (13) $ 1,023 $ 25 The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income. Derivative Financial Instruments and Hedging Activity For the three months ended March 31, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (3) Foreign currency forward contracts $ (1) $ — $ — $ — $ — Effects of cash flow hedges (1) — — — — Cross-currency swaps — — — 8 — Foreign currency forward and options contracts — — — 2 — Effects of net investment hedges (1) — — — 10 — Interest rate swaps (4) — — — (45) — Debt basis adjustment on Long-term borrowings — — — 38 — Effects of fair value hedges — — — (6) — Foreign currency forward contracts (12) (3) — — — Other derivatives (2) — — 5 — 20 Effects of derivatives not designated as hedging instruments $ (12) $ (3) $ 5 $ — $ 20 For the three months ended March 31, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (3) Foreign currency forward contracts $ 27 $ 6 $ — $ — $ — Effects of cash flow hedges 27 6 — — — Cross-currency swaps — — — 9 — Foreign currency forward and option contracts — — — — — Effects of net investment hedges (1) — — — 9 — Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts 7 2 — — 1 Other derivatives (2) — — 15 — — Effects of derivatives not designated as hedging instruments $ 7 $ 2 $ 15 $ — $ 1 (1) Amounts are excluded from effectiveness testing for the three months ended March 31, 2024 and 2023. (2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives. (3) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income. (4) Amount includes $(6) million of interest expense on interest rate derivatives.
Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI	The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges. Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended March 31 2024 2023 Cash flow hedges $ 20 $ (17) Net investment hedges (1) 32 35 (1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis. Fair Value of Assets and Liabilities Measured on a Recurring Basis As of March 31, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Investment securities $ 28 $ — $ — $ 28 $ 31 $ — $ — $ 31 Derivatives — 115 — 115 — 128 — 128 Liabilities: Deferred compensation 263 5 — 268 264 5 — 269 Derivatives — 230 — 230 — 269 — 269 Contingent consideration — — 41 41 — — 44 44 Deferred compensation The deferred compensation liabilities as of March 31, 2024 and December 31, 2023 are comprised of market-based obligations indexed to the S&P 500 index fund and GE HealthCare stock in Level 1, and mutual funds in Level 2.

COMMITMENTS, GUARANTEES, PROD_2

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranties	An analysis of changes in the liability for product warranties follows. For the three months ended March 31 2024 2023 Balance at beginning of period $ 192 $ 193 Current-year provisions 41 49 Expenditures (55) (51) Other changes (2) 2 Balance at end of period $ 175 $ 193

RESTRUCTURING AND OTHER ACTIV_2

RESTRUCTURING AND OTHER ACTIVITIES - NET (Tables)	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	Restructuring and Other Activities For the three months ended March 31 2024 2023 Employee termination costs $ 25 $ 10 Facility and other exit costs 8 1 Asset write-downs 7 1 Total restructuring and other activities – net $ 40 $ 12

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Earnings per Share	Earnings Per Share For the three months ended March 31 (In millions, except per share amounts) 2024 2023 Numerator: Net income $ 388 $ 383 Net (income) loss attributable to noncontrolling interests (14) (11) Net income attributable to GE HealthCare 374 372 Deemed preferred stock dividend of redeemable noncontrolling interest — (183) Net income attributable to GE HealthCare common stockholders $ 374 $ 189 Denominator: Basic weighted-average shares outstanding 456 454 Dilutive effect of common stock equivalents 3 3 Diluted weighted-average shares outstanding 459 457 Basic earnings per share $ 0.82 $ 0.42 Diluted earnings per share $ 0.81 $ 0.41 Antidilutive securities (1) 4 4 (1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash As of March 31, 2024 December 31, 2023 Cash and cash equivalents $ 2,551 $ 2,494 Short-term restricted cash 12 10 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Financial Position 2,563 2,504 Long-term restricted cash (1) 2 2 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Cash Flows $ 2,565 $ 2,506 (1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.
Schedule of Restricted Cash and Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash As of March 31, 2024 December 31, 2023 Cash and cash equivalents $ 2,551 $ 2,494 Short-term restricted cash 12 10 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Financial Position 2,563 2,504 Long-term restricted cash (1) 2 2 Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Cash Flows $ 2,565 $ 2,506 (1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.
Schedule of Inventory	Inventories As of March 31, 2024 December 31, 2023 Raw materials $ 927 $ 961 Work in process 101 91 Finished goods 961 908 Inventories (1) $ 1,989 $ 1,960
Summary of Property, Plant and Equipment	Property, Plant, and Equipment – Net As of March 31, 2024 December 31, 2023 Original cost $ 5,180 $ 5,208 Accumulated depreciation (3,089) (3,064) Right-of-use operating lease assets, net of amortization 354 356 Property, plant, and equipment – net $ 2,445 $ 2,500
Schedule of Other Current Assets	All Other Current and Non-Current Assets As of March 31, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 244 $ 147 Financing receivables – net 96 97 Derivative instruments 101 84 Other (1) 75 61 All other current assets $ 517 $ 389 Prepaid pension asset 727 716 Equity method and other investments 346 357 Financing receivables – net 181 178 Long-term receivables – net 130 124 Inventories 154 147 Contract and other deferred assets 175 168 Other (2) 165 191 All other non-current assets $ 1,878 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of indemnities due from GE, capitalized cloud computing software, tax receivables and derivative instruments.
Schedule of Other Noncurrent Assets	All Other Current and Non-Current Assets As of March 31, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 244 $ 147 Financing receivables – net 96 97 Derivative instruments 101 84 Other (1) 75 61 All other current assets $ 517 $ 389 Prepaid pension asset 727 716 Equity method and other investments 346 357 Financing receivables – net 181 178 Long-term receivables – net 130 124 Inventories 154 147 Contract and other deferred assets 175 168 Other (2) 165 191 All other non-current assets $ 1,878 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of indemnities due from GE, capitalized cloud computing software, tax receivables and derivative instruments.
Schedule of Other Current Liabilities	All Other Current and Non-Current Liabilities As of March 31, 2024 December 31, 2023 Employee compensation and benefit liabilities (1) $ 1,502 $ 1,518 Sales allowances and related liabilities 208 228 Income and indirect tax liabilities including uncertain tax positions 266 260 Product warranties 175 192 Accrued freight and utilities 113 132 Operating lease liabilities 109 110 Derivative instruments (2) 110 128 Interest payable on borrowings 170 87 Environmental and asset retirement obligations 20 21 Other (3) 318 335 All other current liabilities $ 2,993 $ 3,011 Contract liabilities 687 705 Operating lease liabilities 267 273 Environmental and asset retirement obligations 265 265 Income and indirect tax liabilities including uncertain tax positions 207 208 Derivative instruments 114 136 Finance lease obligations 37 38 Sales allowances and related liabilities 24 27 Other (4) 209 225 All other non-current liabilities $ 1,811 $ 1,877 (1) Employee compensation and benefit liabilities consists of incentive compensation and commissions, pension and other postretirement benefit obligations, payroll accruals, other employee related liabilities, and deferred compensation. (2) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to stockholders, and contingent consideration liabilities. (4) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE.
Schedule of Other Noncurrent Liabilities	All Other Current and Non-Current Liabilities As of March 31, 2024 December 31, 2023 Employee compensation and benefit liabilities (1) $ 1,502 $ 1,518 Sales allowances and related liabilities 208 228 Income and indirect tax liabilities including uncertain tax positions 266 260 Product warranties 175 192 Accrued freight and utilities 113 132 Operating lease liabilities 109 110 Derivative instruments (2) 110 128 Interest payable on borrowings 170 87 Environmental and asset retirement obligations 20 21 Other (3) 318 335 All other current liabilities $ 2,993 $ 3,011 Contract liabilities 687 705 Operating lease liabilities 267 273 Environmental and asset retirement obligations 265 265 Income and indirect tax liabilities including uncertain tax positions 207 208 Derivative instruments 114 136 Finance lease obligations 37 38 Sales allowances and related liabilities 24 27 Other (4) 209 225 All other non-current liabilities $ 1,811 $ 1,877 (1) Employee compensation and benefit liabilities consists of incentive compensation and commissions, pension and other postretirement benefit obligations, payroll accruals, other employee related liabilities, and deferred compensation. (2) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to stockholders, and contingent consideration liabilities. (4) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE.
Schedule of Redeemable Noncontrolling Interest	The activity attributable to redeemable noncontrolling interests for the three months ended March 31, 2024 and 2023 is presented below. Redeemable Noncontrolling Interests For the three months ended March 31 2024 2023 Balance at beginning of period $ 165 $ 230 Net income attributable to redeemable noncontrolling interests 11 10 Redemption value adjustments (1) — 183 Distributions to and exercise of redeemable noncontrolling interests and other (2) — (222) Balance at end of period $ 177 $ 201 (1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings. (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The expected redemption payment of $211 million was recognized within All other current liabilities as of March 31, 2023 and was subsequently paid out in the second quarter of 2023.
Schedule of Other Income (Expense)	Other Income (Expense) – Net For the three months ended March 31 2024 2023 Net financing income and investment income (loss) $ (16) $ 13 Equity method income (loss) 1 4 Change in fair value of assumed obligations (8) (13) Other items, net (1) 14 4 Total other income (expense) – net $ (8) $ 8 (1) Other items, net primarily consists of change in tax indemnities with GE, lease income, gains and losses related to derivatives, and licensing and royalty income for the three months ended March 31, 2024, and lease income, gains and losses related to derivatives, and licensing and royalty income for the three months ended March 31, 2023.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2024
Subsidiary, Sale of Stock [Line Items]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued	454,000,000	100
Sale of stock, price per share (in dollars per share)		$ 1
Net transfers from GE, including Spin-Off-related adjustments	$ 2,834		$ 2,834
GE | GE HealthCare Technologies Inc
Subsidiary, Sale of Stock [Line Items]
Ownership percentage				6.70%

REVENUE RECOGNITION - Summary o

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract assets	$ 577	$ 600
Other deferred assets	384	400
Contract and other deferred assets	961	1,000
Non-current contract assets	78	72
Non-current other deferred assets	97	96
Total contract and other deferred assets	$ 1,136	$ 1,168

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,566		$ 2,623
Contract liabilities	687		$ 705
Increase (decrease) in contract liabilities due to customer advances	(56)
Contract liabilities, revenue recognized	741	$ 759
Remaining performance obligation, amount	14,313
Cost of products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,742
Cost of products | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	98%
Remaining performance obligation, period	2 years
Cost of services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,570
Cost of services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	65%
Remaining performance obligation, period	2 years
Cost of services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	94%
Remaining performance obligation, period	5 years

SEGMENT INFORMATION- Narrative

SEGMENT INFORMATION- Narrative (Details)	3 Months Ended
	Mar. 31, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 4,650	$ 4,707
EBIT	681	664
Restructuring costs	(40)	(12)
Acquisition and disposition-related benefits (charges)	0	(1)
Gain (loss) on business and asset dispositions	0	0
Spin-Off and separation costs	(60)	(58)
Amortization of acquisition-related intangible assets	(31)	(31)
Investment revaluation gain (loss)	(20)	5
Interest and other financial charges – net	(122)	(136)
Non-operating benefit income (costs)	102	115
Income before income taxes	512	546
Operating segments | Imaging
Segment Reporting Information [Line Items]
Total revenues	2,466	2,496
EBIT	240	191
Operating segments | Imaging | Radiology
Segment Reporting Information [Line Items]
Total revenues	2,062	2,088
Operating segments | Imaging | Interventional Guidance
Segment Reporting Information [Line Items]
Total revenues	403	408
Operating segments | Ultrasound
Segment Reporting Information [Line Items]
Total revenues	824	859
EBIT	182	207
Operating segments | PCS
Segment Reporting Information [Line Items]
Total revenues	747	781
EBIT	81	109
Operating segments | PCS | Monitoring Solutions
Segment Reporting Information [Line Items]
Total revenues	527	552
Operating segments | PCS | Life Support Solutions
Segment Reporting Information [Line Items]
Total revenues	220	229
Operating segments | PDx
Segment Reporting Information [Line Items]
Total revenues	599	558
EBIT	178	155
Other
Segment Reporting Information [Line Items]
Total revenues	15	13
EBIT	$ (1)	$ 2

RECEIVABLES - Current Receivabl

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (102)	$ (98)
Chargebacks	136	144
Nonrelated party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current customer receivables	3,148	3,339
Non-income based tax receivables	151	166
Other sundry receivables	127	118
Current sundry receivables	278	284
Allowance for credit losses	(102)	(98)
Total current receivables – net	$ 3,324	$ 3,525

RECEIVABLES - Long-Term Receiva

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Receivables [Abstract]
Long-term customer receivables	$ 57	$ 55
Non-income based tax receivables	25	26
Other sundry receivables	78	73
Long-term sundry receivables	102	99
Allowance for credit losses	(30)	(30)
Total long-term receivables – net	$ 130	$ 124

FINANCING RECEIVABLES - Schedul

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (3)	$ (3)
Current financing receivables, net	96	97
Allowance for credit losses, noncurrent	(5)	(5)
Non-current financing receivables, net	181	178
Loans, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	29	29
Non-current financing receivables, gross	36	37
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	71	71
Non-current financing receivables, gross	$ 149	$ 146

FINANCING RECEIVABLES - Narrati

FINANCING RECEIVABLES - Narrative (Details)	Mar. 31, 2024	Dec. 31, 2023
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	7%	6%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	6%	5%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	5%	5%

LEASES (Details)

LEASES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Leases [Abstract]
Operating lease liability	$ 376		$ 383
Operating lease cost	$ 60	$ 56

ACQUISITIONS, GOODWILL, AND O_3

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Feb. 17, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Consideration transferred, upfront payment		$ 0	$ 127
Goodwill		12,927		$ 12,936
Amortization of acquisition-related intangible assets		$ 80	$ 96
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired	100%
Consideration transferred, upfront payment	$ 127
Consideration transferred, holdback payment	10
Contingent consideration	13
Goodwill	94
Intangible assets	60
Deferred tax liabilities	$ 3

ACQUISITIONS, GOODWILL, AND O_4

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 12,936
Acquisitions	0
Foreign exchange and other	(10)
Ending balance	12,927
Imaging
Goodwill [Roll Forward]
Beginning balance	4,431
Acquisitions	0
Foreign exchange and other	(4)
Ending balance	4,427
Ultrasound
Goodwill [Roll Forward]
Beginning balance	3,933
Acquisitions	0
Foreign exchange and other	(5)
Ending balance	3,928
PCS
Goodwill [Roll Forward]
Beginning balance	2,038
Acquisitions	0
Foreign exchange and other	(1)
Ending balance	2,037
PDx
Goodwill [Roll Forward]
Beginning balance	2,534
Acquisitions	0
Foreign exchange and other	0
Ending balance	$ 2,534

BORROWINGS - Narrative (Details

BORROWINGS - Narrative (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) series	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	$ 114,000,000
Guarantee obligation, carrying value	4,000,000	$ 4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	717,000,000	751,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	33,000,000	39,000,000
Senior notes | Senior unsecured notes
Debt Instrument [Line Items]
Debt, principal amount	$ 8,250,000,000
Number of debt series | series	6
Debt repayments	$ 0
Line of credit | Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Debt repayments	150,000,000
Total amount of debt repaid	1,000,000,000
Line of credit | Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding	$ 0	$ 0
Line of credit | Revolving credit facility | 5-Year Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term	5 years
Maximum borrowing capacity	$ 2,500,000,000
Line of credit | Revolving credit facility | 364-Day Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term	364 days
Maximum borrowing capacity	$ 1,000,000,000
Line of credit | Unsecured debt | Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Debt, term	3 years
Maximum borrowing capacity	$ 2,000,000,000

BORROWINGS - Schedule of Long-T

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Principal debt issued	$ 9,301	$ 9,452
Less: Unamortized debt issuance costs and discounts	33	35
Add: Cumulative basis adjustment for fair value hedges	(13)	25
Total borrowings	9,255	9,442
Less: Short-term borrowings	1,008	1,006
Long-term borrowings	8,247	8,436
Long-term borrowings, current	$ 1,003	1,002
Senior notes | 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes | 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes | 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes | 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes | 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes | 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit | Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Principal debt issued	1,000	1,150
Other
Debt Instrument [Line Items]
Principal debt issued	$ 51	$ 52

POSTRETIREMENT BENEFIT PLANS -

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Plan asset or obligation reporting threshold	$ 50
Defined benefit plan, expected future employer contributions, next fiscal year	336
Defined contribution plan, employer contribution amount	32	$ 33
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	39
GE HealthCare Supplemental Pension Plan | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	27
Other Pension Plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	$ 21

POSTRETIREMENT BENEFIT PLANS _2

POSTRETIREMENT BENEFIT PLANS - Components of Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (102)	$ (115)
Pension Plans | Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	7	8
Interest cost	227	240
Expected return on plan assets	(283)	(293)
Amortization of net loss (gain)	(19)	(31)
Amortization of prior service cost (credit)	2	0
Non-operating	(73)	(84)
Net periodic expense (income)	(66)	(76)
Pension Plans | Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	6	6
Interest cost	50	52
Expected return on plan assets	(63)	(63)
Amortization of net loss (gain)	5	2
Amortization of prior service cost (credit)	0	(1)
Non-operating	(8)	(10)
Net periodic expense (income)	(2)	(4)
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	2	2
Interest cost	13	15
Expected return on plan assets	0	0
Amortization of net loss (gain)	(15)	(16)
Amortization of prior service cost (credit)	(22)	(22)
Non-operating	(24)	(23)
Net periodic expense (income)	$ (22)	$ (21)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	24.20%	29.90%
Deferred tax liabilities, undistributed foreign earnings		$ 30

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	$ 7,145	$ 9,362
Other comprehensive income (loss) before reclassifications – net of taxes	(58)	31
Reclassifications from AOCI – net of taxes	(37)	(78)
Other comprehensive income (loss)	(95)	(47)
Spin-Off related adjustments – net of taxes		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0
Equity, ending balance	7,423	6,696
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(691)	(1,878)
Equity, ending balance	(787)	75
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,706)	(1,845)
Other comprehensive income (loss) before reclassifications – net of taxes	(76)	57
Reclassifications from AOCI – net of taxes	0	0
Other comprehensive income (loss)	(76)	57
Spin-Off related adjustments – net of taxes		28
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0
Equity, ending balance	(1,781)	(1,760)
Other comprehensive income (loss) before reclass, tax	(7)	(11)
Reclass from AOCI, tax	0	0
Spin-Off related adjustments, tax		0
Pension and Other Postretirement Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	1,033	(42)
Other comprehensive income (loss) before reclassifications – net of taxes	2	(13)
Reclassifications from AOCI – net of taxes	(38)	(52)
Other comprehensive income (loss)	(35)	(65)
Spin-Off related adjustments – net of taxes		1,972
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0
Equity, ending balance	997	1,865
Other comprehensive income (loss) before reclass, tax	(1)	2
Reclass from AOCI, tax	12	16
Spin-Off related adjustments, tax		(509)
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(18)	9
Other comprehensive income (loss) before reclassifications – net of taxes	15	(13)
Reclassifications from AOCI – net of taxes	0	(26)
Other comprehensive income (loss)	16	(39)
Spin-Off related adjustments – net of taxes		0
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0
Equity, ending balance	(2)	(30)
Other comprehensive income (loss) before reclass, tax	(4)	4
Reclass from AOCI, tax	$ 0	7
Spin-Off related adjustments, tax		$ 0

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Cash flow hedge loss to be reclassified within 12 months	$ 3
Derivative, potential effect of rights of offset to assets and liabilities	40
Estimated fair value
Derivative [Line Items]
Borrowings	9,807	$ 9,959
Carrying value
Derivative [Line Items]
Borrowings	$ 9,255	$ 9,442

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Gross Notional	$ 9,991	$ 9,591
Fair Value – Assets	115	128
Fair Value – Liabilities	230	269
Designated as hedging instrument | Cash flow hedges
Derivative [Line Items]
Gross Notional	1,176	1,356
Fair Value – Assets	15	8
Fair Value – Liabilities	15	30
Designated as hedging instrument | Cash flow hedges | Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	1,176	1,356
Fair Value – Assets	15	8
Fair Value – Liabilities	15	30
Designated as hedging instrument | Net investment hedges
Derivative [Line Items]
Gross Notional	3,154	3,200
Fair Value – Assets	10	9
Fair Value – Liabilities	182	215
Designated as hedging instrument | Net investment hedges | Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,178	2,209
Fair Value – Assets	0	0
Fair Value – Liabilities	174	204
Designated as hedging instrument | Net investment hedges | Foreign currency forward and options contracts
Derivative [Line Items]
Gross Notional	976	991
Fair Value – Assets	10	9
Fair Value – Liabilities	8	11
Designated as hedging instrument | Fair value hedges
Derivative [Line Items]
Gross Notional	1,700	1,000
Fair Value – Assets	3	35
Fair Value – Liabilities	16	10
Designated as hedging instrument | Fair value hedges | Interest rate swaps
Derivative [Line Items]
Gross Notional	1,700	1,000
Fair Value – Assets	3	35
Fair Value – Liabilities	16	10
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	3,961	4,035
Fair Value – Assets	87	76
Fair Value – Liabilities	17	14
Not designated as hedging instrument | Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	3,586	3,597
Fair Value – Assets	8	19
Fair Value – Liabilities	15	12
Not designated as hedging instrument | Other derivatives
Derivative [Line Items]
Gross Notional	375	438
Fair Value – Assets	78	57
Fair Value – Liabilities	$ 1	$ 2

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Cumulative Basis Adjustment for Fair value Hedges (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Long-term borrowings designated in fair value hedges	$ 1,683	$ 1,023
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term borrowings	Long-term borrowings
Cumulative basis adjustment included in the carrying amount	$ (13)	$ 25

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Cash flow hedges	$ 20	$ (17)
Net investment hedges	$ 32	$ 35

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ 0	$ 0
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	5	15
SG&A | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	0	0
SG&A | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
SG&A | Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
SG&A | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
SG&A | Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
SG&A | Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	5	15
Interest and other financial charges – net
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	10	9
Effects of fair value hedges	(6)	0
Effects of derivatives not designated as hedging instruments	0	0
Interest and other financial charges – net | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	0	0
Interest and other financial charges – net | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	8	9
Interest and other financial charges – net | Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	2	0
Interest and other financial charges – net | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(45)	0
Interest and other financial charges – net | Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	38	0
Interest and other financial charges – net | Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0
Interest expense | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(6)
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	20	1
Other | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	0	1
Other | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Other | Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Other | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Other | Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Other | Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	20	0
Cost of products | Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	27
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	(12)	7
Cost of products | Cost of revenue | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	27
Effects of derivatives not designated as hedging instruments	(12)	7
Cost of products | Cost of revenue | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Cost of products | Cost of revenue | Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Cost of products | Cost of revenue | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Cost of products | Cost of revenue | Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Cost of products | Cost of revenue | Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0
Cost of services | Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	6
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	(3)	2
Cost of services | Cost of revenue | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	6
Effects of derivatives not designated as hedging instruments	(3)	2
Cost of services | Cost of revenue | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Cost of services | Cost of revenue | Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Cost of services | Cost of revenue | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Cost of services | Cost of revenue | Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Cost of services | Cost of revenue | Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_8

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Assets:
Investment securities	$ 28	$ 31
Derivatives	115	128
Liabilities:
Deferred compensation	268	269
Derivatives	230	269
Contingent consideration	41	44
Level 1
Assets:
Investment securities	28	31
Derivatives	0	0
Liabilities:
Deferred compensation	263	264
Derivatives	0	0
Contingent consideration	0	0
Level 2
Assets:
Investment securities	0	0
Derivatives	115	128
Liabilities:
Deferred compensation	5	5
Derivatives	230	269
Contingent consideration	0	0
Level 3
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Deferred compensation	0	0
Derivatives	0	0
Contingent consideration	$ 41	$ 44

COMMITMENTS, GUARANTEES, PROD_3

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) $ in Millions	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 114

COMMITMENTS, GUARANTEES, PROD_4

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 192	$ 193
Current-year provisions	41	49
Expenditures	(55)	(51)
Other changes	(2)	2
Balance at end of period	$ 175	$ 193

RESTRUCTURING AND OTHER ACTIV_3

RESTRUCTURING AND OTHER ACTIVITIES - NET - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring expenses, net	$ 40	$ 12
Expected restructuring expense remaining	25
Restructuring liabilities	$ 76		$ 68

RESTRUCTURING AND OTHER ACTIV_4

RESTRUCTURING AND OTHER ACTIVITIES - NET - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 25	$ 10
Facility and other exit costs	8	1
Asset write-downs	7	1
Total restructuring and other activities – net	$ 40	$ 12

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net income	$ 388	$ 383
Net (income) loss attributable to noncontrolling interests	(14)	(11)
Net income attributable to GE HealthCare	374	372
Deemed preferred stock dividend of redeemable noncontrolling interest	0	(183)
Net income attributable to GE HealthCare common stockholders	$ 374	$ 189
Denominator:
Basic weighted-average shares outstanding	456	454
Dilutive effect of common stock equivalents (in shares)	3	3
Diluted weighted-average shares outstanding	459	457
Basic earnings per share (in dollars per share)	$ 0.82	$ 0.42
Diluted earnings per share (in dollars per share)	$ 0.81	$ 0.41
Antidilutive securities (in shares)	4	4

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,551	$ 2,494
Short-term restricted cash	12	10
Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Financial Position	2,563	2,504
Long-term restricted cash	2	2
Total Cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated Statements of Cash Flows	$ 2,565	$ 2,506	$ 2,334	$ 1,451

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 927	$ 961
Work in process	101	91
Finished goods	961	908
Inventories	$ 1,989	$ 1,960

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Original cost	$ 5,180	$ 5,208
Accumulated depreciation	(3,089)	(3,064)
Right-of-use operating lease assets, net of amortization	354	356
Property, plant, and equipment – net	$ 2,445	$ 2,500

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Noncurrent Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses and deferred costs	$ 244	$ 147
Financing receivables – net	96	97
Derivative instruments	101	84
Other	75	61
All other current assets	517	389
Prepaid pension asset	727	716
Equity method and other investments	346	357
Financing receivables – net	181	178
Long-term receivables – net	130	124
Inventories	154	147
Contract and other deferred assets	175	168
Other	165	191
All other non-current assets	$ 1,878	$ 1,881

SUPPLEMENTAL FINANCIAL INFORM_7

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Noncurrent Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Employee compensation and benefit liabilities	$ 1,502	$ 1,518
Sales allowances and related liabilities	208	228
Income and indirect tax liabilities including uncertain tax positions	266	260
Product warranties	175	192
Accrued freight and utilities	113	132
Operating lease liabilities	109	110
Derivative instruments	110	128
Interest payable on borrowings	170	87
Environmental and asset retirement obligations	20	21
Other	318	335
Contract liabilities	687	705
Operating lease liabilities	267	273
Environmental and asset retirement obligations	265	265
Income and indirect tax liabilities including uncertain tax positions	207	208
Derivative instruments	114	136
Finance lease obligations	$ 37	$ 38
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Sales allowances and related liabilities	$ 24	$ 27
Other	209	225
All other non-current liabilities	1,811	1,877
Nonrelated party
Related Party Transaction [Line Items]
All other current liabilities	$ 2,993	$ 3,011

SUPPLEMENTAL FINANCIAL INFORM_8

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Supplier Finance Program [Line Items]
Supplier finance program, payment terms, maximum threshold	180 days
Supplier finance program obligation	$ 384	$ 365
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	150 days

SUPPLEMENTAL FINANCIAL INFORM_9

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 165	$ 230
Net income attributable to redeemable noncontrolling interests	11	10
Redemption value adjustments	0	183
Distributions to and exercise of redeemable noncontrolling interests and other	0	(222)
Balance at end of period	$ 177	201
Noncontrolling interest redemption payment		$ 211

SUPPLEMENTAL FINANCIAL INFOR_10

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net financing income and investment income (loss)	$ (16)	$ 13
Equity method income (loss)	1	4
Change in fair value of assumed obligations	(8)	(13)
Other items, net	14	4
Total other income (expense) – net	$ (8)	$ 8

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
All other non-current assets	$ 1,878		$ 1,881
All other non-current liabilities	1,811		1,877
Related party
Related Party Transaction [Line Items]
All other non-current assets	80		81
All other non-current liabilities	33		$ 33
Transition Services Agreement | Related party
Related Party Transaction [Line Items]
Transaction amount	$ 53	$ 108

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions		3 Months Ended
	Apr. 01, 2024	Mar. 31, 2024	Mar. 31, 2023
Subsequent Event [Line Items]
Consideration, net of cash acquired		$ 0	$ 127
Subsequent event | MIM Software
Subsequent Event [Line Items]
Percent of interest acquired	100%
Consideration, net of cash acquired	$ 258
Contingent consideration (up to)	$ 35